We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02035813
Recruitment Status : Active, not recruiting
First Posted : January 14, 2014
Last Update Posted : July 28, 2022
Information provided by (Responsible Party):
Prof. W. Janni, University of Ulm

Brief Summary:
Several studies have indicated that determining prevalence and number of circulating tumor cells (CTCs) at various time points during treatment may be an effective tool for assessing treatment efficacy in metastatic breast cancer (MBC). However, even if the prognostic value of CTCs in MBC is well understood, the role of both CTC prevalence and CTC phenotype in predicting treatment response needs further investigation. DETECT IV is a prospective, multicenter, open-label, phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs). Additional research on CTC dynamics and characteristics will provide a better understanding of the prognostic and predictive value of CTCs and is one step into a more personalized therapy for MBC.

Condition or disease Intervention/treatment Phase
HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer HER2-negative Circulating Tumor Cells Postmenopausal Female Patients Drug: Ribociclib Drug: Eribulin Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 116 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: DETECT IV - A Prospective, Multicenter, Open-label, Phase II Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
Study Start Date : January 2014
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Ribociclib in combination with standard endocrine therapy
Postmenopausal female patients with hormone-receptor positive, HER2-negative metastatic breast cancer with HER2-negative circulating tumor cells (CTCs) and indication for standard endocrine therapy.
Drug: Ribociclib
Ribociclib/Everolimus in combination with endocrine therapy
Other Name: Kisqali

Experimental: Eriubulin
Patients with hormone-receptor positive, HER2-negative metastatic breast cancer and indication to chemother-apy or patients with triple-negative metastatic breast cancer, both with HER2-negative circulating tumor cells (CTCs).
Drug: Eribulin
Other Name: Halaven

Primary Outcome Measures :
  1. Progression free survival (PFS) [ Time Frame: 8-12 weeks ]
    Time interval from randomization until progressive disease (PD) or death from any cause, whichever comes first

Secondary Outcome Measures :
  1. Overall response rate [ Time Frame: 8-12 weeks ]
    Rate of complete (CR) and partial responses (PR) in patients with whom target lesions were defined

  2. Disease control rate (DCR) [ Time Frame: 8-12 weeks ]
    rate of patients who were assessed as having a PR or a CR or who had stable disease (SD) for at least 6 months

  3. Overall survival (OS) [ Time Frame: 4 weeks ]
    Time from randomization until death of any cause

  4. Dynamic of CTCs [ Time Frame: 8-12 weeks ]
    Descriptive statistics of regular CTC counts

  5. For Everolimus/Ribociclib cohort only: Levels of pS6 [ Time Frame: 8-12 weeks ]
    Descriptive statistics of pS6 levels at baseline, at first radiological tumor assessment after about 12 weeks, and at the time of progression

  6. For Everolimus/Ribociclib cohort only: Change in the activation of the PI3K/Akt/mTOR-pathway in CTCs [ Time Frame: 8-12 weeks ]
    Descriptive statistics of changes in the activation of the PI3K/Akt/mTOR-pathway in CTCs as assessed by longitudinal comparisons (at baseline, after 12 weeks, at time of progression)

  7. For Everolimus/Ribociclib cohort only: Estrogen-receptor 1 (ESR-1) mutations in CTCs [ Time Frame: 8-12 weeks ]
    Estrogen-receptor 1 (ESR-1) mutations in CTCs at baseline, after 12 weeks and at time of progression

  8. For Eribulin cohort only: New metastasis-free survival (nMFS) [ Time Frame: 8-12 weeks ]
    New metastasis-free survival (nMFS), defined as time from recruitment to death or progression due to appearance of a new metastasis, whichever comes first. If a patient has not had an event, nMFS is censored at the date of last adequate tumor as-sessment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Both cohorts:

  • Indication for an endocrine therapy (Histological confirmation of estrogen receptor positive (ER+) and/or progesterone receptor positive (PgR+) breast cancer).
  • Up to two lines of previous cytostatic treatment for MBC.
  • Any endocrine therapy in the history is allowed.
  • Disease progression following prior treatment with endocrine therapy (endocrine therapy does not have to be the last therapy before inclusion in the trial).
  • Postmenopausal women. The investigator must confirm postmenopausal status Postmenopausal status is defined either by

    • Age ≥ 55 years and one year or more of amenorrhea
  • - Age < 55 years and one year or more of amenorrhea and postmenopausal levels of FSH and LH
  • - Prior hysterectomy and has postmenopausal levels of FSH and LH
  • - Surgical menopause with bilateral oophorectomy
  • Everolimus cohort:
  • Cholesterol ≤ 2.0 × ULN
  • Ribociclib cohort:
  • Standard 12-lead ECG values assessed by the local laboratory:
  • - QTcF interval at screening < 450 msec (using Fridericia's correction)
  • - Resting heart rate 50-90 bpm
  • INR ≤ 1,5 (ribocilclib cohort)
  • Patients must have the following laboratory values within normal limits or corrected to within normal lim-its with supplemets before the first dose of study medication:
  • -Sodium
  • -Potassium
  • -Total calcium

For Eribulin only:

  • Either hormone-receptor negative MBC or hormone-receptor positive MBC with indication for chemotherapy
  • Up to three previous chemotherapy treatment lines for metastatic disease
  • In case of patients of child bearing potential:

    • Negative pregnancy test (minimum sensitivity 25IU/L or equivalent units of HCG) within 7 days prior to recruitment
    • Contraception by means of a reliable method (i.e. non-hormonal contraception, IUD, a dou-ble barrier method, vasectomy of the sexual partner, complete sexual abstinence). Patient must consent in maintaining such contracep-tion until 3 months after completion of study treatment

Exclusion Criteria:

In General for both study cohorts:

  1. Treatment with other investigational agents of any type or anticancer therapy during the trial, within 2 weeks prior to the start of treatment.
  2. Adverse events due to prior anticancer therapy which are > Grade 1 (NCI CTCAE) and therapeutically relevant at time of treatment start.
  3. Known HIV infection.
  4. Current active hepatitis B or C, cliniclally relevant known liver dysfunction, e.g. according to Child Pugh Classifica-tion class B and C, or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gall-stones, liver metastases or stable chronic non-viral liver disease per investigator assessment).
  5. Concurrent disease or condition that might interfere with adequate assessment or evaluation of study data, or any medical disorder that would make the patient's participation unreasonably hazardous.
  6. Other malignant diseases within the last 3 years (apart from carcinoma in situ of the cervix or non-melanoma skin cancer)
  7. Dementia, altered mental status, or any psychiatric or social condition which would prohibit the understanding or rendering of informed consent or which might interfere with the patient's adherence to the protocol.
  8. Life expectancy < 3 months.
  9. Male gender.

For Everolimus/Ribociclib only:

  • Known hypersensitivity to any of the excipients of ribociclib, everolimus or any of the other given drugs.
  • Known hypersensitivity to lecithin (soya) and pea-nuts (ribocilib-cohort)
  • Disease or condition, which might restrain the ability to take or resorb oral medication. This includes malabsorption syndrome, requirement for intrave-nous (IV) alimentation, prior surgical procedures af-fecting absorption (for example resection of small bowel or stomach), uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis) and any other diseases significantly affecting gas-trointestinal function as well as inability to swallow and retain oral medication for any other reason.

For Eribulin only:

  • History of hypersensitivity reactions attributed to eribulin.
  • Pre-existing neuropathy grade 3 or higher.
  • Severe Congenital long QT syndrome.
  • Pregnancy or nursing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02035813

Layout table for location information
University Hospital Ulm -Department of Gynecology
Ulm, Baden-Württemberg, Germany, 89075
Sponsors and Collaborators
Prof. W. Janni
Layout table for investigator information
Principal Investigator: Tanja Fehm, MD, PhD University Hospital Düsseldorf -Department of Gynecology
Study Director: Wolfgang Janni, MD, PhD University Hospital Ulm -Department of Gynecology
Additional Information:
Layout table for additonal information
Responsible Party: Prof. W. Janni, University hospital Ulm - Department of Gynecology, University of Ulm
ClinicalTrials.gov Identifier: NCT02035813    
Other Study ID Numbers: D-IV
2013-001269-18 ( EudraCT Number )
First Posted: January 14, 2014    Key Record Dates
Last Update Posted: July 28, 2022
Last Verified: July 2022
Keywords provided by Prof. W. Janni, University of Ulm:
metastatic breast cancer
circulating tumor cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplastic Cells, Circulating
Neoplasms by Site
Breast Diseases
Skin Diseases
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes